Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue.

This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including:

  • HIV Co-infection
  • HBV Co-infection
  • HCV co-infection

Likely downstream events associated with chronic HCV infection include:

  • Cirrhosis of the liver
  • Hepatocellular carcinoma
  • Excess mortality associated with liver disease / decompensated liver function

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Chronic Hepatitis C market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Chronic Hepatitis C and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Chronic Hepatitis C prevalent population.
  • Identify sub-populations within Crohn’s disease which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Chronic Hepatitis C patients.